Heme Exporter FLVCR1a Regulates Heme Synthesis and Degradation and Controls Activity of Cytochromes P450  by Vinchi, Francesca et al.
Gastroenterology 2014;146:1325–1338BASIC AND TRANSLATIONAL—LIVER
Heme Exporter FLVCR1a Regulates Heme Synthesis and
Degradation and Controls Activity of Cytochromes P450
Francesca Vinchi, Giada Ingoglia, Deborah Chiabrando, Sonia Mercurio, Emilia Turco,
Lorenzo Silengo, Fiorella Altruda, and Emanuela Tolosano
Molecular Biotechnology Center and Department of Molecular Biotechnology and Health Sciences, University of Torino,
Torino, ItalyBA
SI
C
AN
D
TR
AN
SL
AT
IO
NA
L
LI
VE
RBACKGROUND & AIMS: The liver has one of the highest rates of
heme synthesis of any organ. More than 50% of the heme syn-
thesized in the liver is used for synthesis of P450 enzymes, which
metabolize exogenous and endogenous compounds that include
natural products, hormones, drugs, and carcinogens. Feline
leukemia virus subgroup C cellular receptor 1a (FLVCR1a) is
plasmamembrane heme exporter that is ubiquitously expressed
and controls intracellular heme content in hematopoietic line-
ages. We investigated the role of Flvcr1a in liver function inmice.
METHODS: We created mice with conditional disruption of
Mfsd7b, which encodes Flvcr1a, in hepatocytes (Flvcr1a ﬂ/ﬂ;alb-
cre mice). Mice were analyzed under basal conditions, after
phenylhydrazine-induced hemolysis, and after induction of
cytochromes P450 synthesis. Livers were collected and
analyzed by histologic, quantitative real-time polymerase chain
reaction, and immunoblot analyses. Hepatic P450 enzymatic
activities were measured. RESULTS: Flvcr1aﬂ/ﬂ;alb-cre mice
accumulated heme and iron in liver despite up-regulation of
heme oxygenase 1, ferroportin, and ferritins. Hepatic heme
export activity of Flvcr1a was closely associated with heme
biosynthesis, which is required to sustain cytochrome induc-
tion. Upon cytochromes P450 stimulation, Flvcr1aﬂ/ﬂ;alb-cre
mice had reduced cytochrome activity, associated with accu-
mulation of heme in hepatocytes. The expansion of the cytosolic
heme pool in these mice was likely responsible for the early
inhibition of heme synthesis and increased degradation of
heme, which reduced expression and activity of cytochromes
P450. CONCLUSIONS: In livers of mice, Flvcr1a maintains a free
heme pool that regulates heme synthesis and degradation as
well as cytochromes P450 expression and activity. These ﬁnd-
ings have important implications for drug metabolism.Keywords: ALAS1; CYP; Flvcr; HO-1; Flvcr1.
erobic cells require heme as the prosthetic moiety ofAbbreviations used in this paper: ALA, 5-aminolevulinic acid; ALAS, 5-
aminolevulinic acid synthase; Be(a)P, benzo(a)pyrene; CYP, cytochrome
P450; FLVCR1a, feline leukemia virus subgroup C cellular receptor 1a;
Fpn, ferroportin; HO, heme oxygenase; mRNA, messenger RNA.
© 2014 by the AGA Institute
0016-5085
http://dx.doi.org/10.1053/j.gastro.2014.01.053
Open access under CC BY-NC-ND license.Aseveral hemoproteins, including hemoglobin, cyto-
chromes, myoglobin, catalases, and peroxidases.1 In addi-
tion, heme plays important regulatory roles in cell signaling
and in control of gene expression.2 Heme biosynthesis
occurs partially in the mitochondria and partially in the
cytoplasm by a multistep pathway involving 8 enzymatic
reactions. 5-Aminolevulinic acid synthase (ALAS), which
catalyzes the condensation of glycine and succinyl-CoA to
form ALA (5-aminolevulinic acid) in the mitochondrion, is
the ﬁrst and rate-controlling enzyme of heme biosynthesis.1The rate of heme synthesis is balanced by the rate of its
degradation through heme oxygenases (HO-1 and HO-2) to
ensure that heme supply is adequate to physiological needs,
without a signiﬁcant accumulation in excess.3 The tight
control of heme synthesis vs heme degradation is essential
because free heme is a pro-oxidant and toxic molecule.4,5
Both heme synthesis and heme degradation are tunely
regulated by heme itself. Heme controls Alas1 transcription,
the stability of Alas1 messenger RNA (mRNA) and the
accumulation of the mature protein in the mitochondrion.6–8
On the opposite side, heme controls Ho-1 gene expression
by removing the transcriptional repressor BACH1 from its
promoter.9 The pool of heme that exerts this control, the
so-called “free” or “regulatory” heme pool, is determined by
a balance between heme synthesis and degradation and
because of its small size, dynamic properties, and ability to
readily exchange with heme-containing proteins, reﬂects the
overall status of cellular heme content.10
Recently, heme export through the cell-surface trans-
porter feline leukemia virus subgroup C cellular receptor 1a
(Flvcr1a) was proposed as an additional control step to
prevent the intracellular accumulation of heme.11,12 Flvcr1
gene is essential for erythropoiesis and systemic iron
homeostasis.12 It encodes for 2 proteins, FLVCR1a and
FLVCR1b, expressed at the plasma membrane and on the
mitochondrion, respectively. FLVCR1a belongs to the SLC49
family of the major facilitator superfamily of transporters
with 12 hydrophobic transmembrane domains.12,13 FLVCR1b
is a shorter protein with only 6 transmembrane domains,
supposed to homodimerize to form a functional trans-
porter.13 We recently demonstrated a crucial role for
FLVCR1b in the last step of heme biosynthetic pathway, ie,
heme export from mitochondria.13 On the other hand,
FLVCR1a exerts its heme export activity at the plasma
membrane and avoids intracellular heme loading. Previous
studies showed that FLVCR1a-mediated heme export in
macrophages prevents heme-derived iron accumulation after
Figure 1. Flvcr1a deletion
in the liver alters hepatic
heme/iron homeostasis.
Data on the livers of 2- (A–
D) and 6-month-old (A–F)
Flvcr1aﬂ/ﬂ and Flvcr1aﬂ/ﬂ;
alb-cre mice are shown.
Heme (A) and iron (B) con-
tent. (A) n ¼ 10. (B) n ¼ 10.
Liver sections of 6-month-
old mice stained with Perl’s
reaction are shown on the
right. Scale bar ¼ 300 mm.
(C) HO activity and bile
bilirubin content, n ¼ 5. (D)
malondialdehyde (MDA)
content, n ¼ 14.
(E) Quantitative real-time
polymerase chain reaction
(qRT-PCR) analysis of
Flvcr1a, Ho-1, Fpn, H- and
L-ferritin (Ft) mRNA level
(n ¼ 6) and representative
Western blots of HO-1,
L- and H-Ft and FPN pro-
tein, n ¼ 10. (F) qRT-PCR
analysis of Txnrd1, g-gcs,
and Sod1 mRNA level
(n ¼ 5). Unpaired T test
analysis with Welch’s cor-
rectionwas performed. AU,
arbitrary units; RQ, relative
quantity. *P < .05; **P <
.01; ***P < .001.
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Figure 2. FLVCR1a is required to export heme on heme accumulation inside hepatocytes. Data on the liver of hemin-treated
Flvcr1aﬂ/ﬂ and Flvcr1aﬂ/ﬂ;alb-cre mice are shown. Heme content in the liver (A, C) and bilirubin content in the bile (B) at
different time points after 30 mmol/kg heme injection. In (B, C) mice were injected with 15 mmol/kg Tin-Protoporphyrin IX
(SnPP) 30 minutes before heme treatment (n ¼ 5). (D) SnPP content in the liver 4 hours after SnPP injection (n ¼ 4).
(E) Quantitative real-time polymerase chain reaction analysis (qRT-PCR) of Flvcr1a, Ho-1, Fpn, H- and L-ferritin (Ft), Txnrd1,
and g-gcs mRNA level (n ¼ 6). (F) Representative Western blots of HO-1, L- and H-Ft protein (n ¼ 4). Two-way analysis of
variance with Bonferroni post-test analysis and unpaired T test analysis with Welch’s were performed on data in (A), (B), (C),
(F), and in (D), respectively. *P < .05; **P < .01; ***P < .001; ****P < .0001.
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HeLa cells results in cytosolic heme loading, HO-1 induction,
and oxidative stress. Finally, Flvcr1a deletion in mice causes
embryo lethality due to extended hemorrhages.13
The liver is one of the body compartments with the
highest heme rate synthesis. More than 50% of the heme
synthesized in the liver is committed to the synthesis of
cytochromes P450 (CYPs),15 the major enzymes involved in
drug metabolism.16 As the prosthetic moiety of all CYPs,
heme is responsible for the catalytic activity of these en-
zymes. In addition, the free heme pool also regulates CYP
protein synthesis and disposal.10
Here we show that Flvcr1a function in hepatocytes is
critical for the maintenance of a heme pool that controls CYP
expression and activity.
Methods
Mice and Treatment
Mice used in these studies were 2/3-month-old and 6-
month-old littermates, maintained on a standard chow diet
and kept with free access to food and water. All experiments
were approved by the animal ethical committee of the University
of Torino (Italy).
Heme and Iron Content
Heme content in tissues and bile was quantiﬁed by the oxalic
acid method. Tissue nonheme iron content was determined by a
colorimetric method using 4,7-diphenyl-1, 10-phenantroline
disulfonic acid (Sigma, St Louis, MO) as chromogen.
HO Activity
HO activity was measured by spectrophotometric determi-
nation of bilirubin produced from hemin added as substrate.
Lipid Peroxidation
Lipid peroxidation from tissue extracts was measured using
the colorimetric assay kit Bioxytech LPO-586 from Oxis Inter-
national (Portland, OR).
Quantitative Real-Time Polymerase
Chain Reaction
Total RNA was extracted using Pure Link RNA Mini Kit
(Ambion, Life Technologies Italia, Torino, Italy). One microgram
total RNA was reverse transcribed using M-MLV reverse tran-
scriptase and random primers (Life Technologies Italia). Quan-
titative real-time polymerase chain reaction was performed on a
7300 Real Time PCR System (Applied Biosystems, Life Tech-
nologies Italia). Primers and probes were designed using the
ProbeFinder software (www.roche-applied-science.com).=
Figure 3. FLVCR1a-mediated heme export function is strictly
Flvcr1aﬂ/ﬂ and Flvcr1aﬂ/ﬂ;alb-cre mice are shown. Heme (A) and
Quantitative real-time polymerase chain reaction analysis of Flvc
level in the liver (n ¼ 4). (D, E) Heme uptake and reactive oxyge
from the liver of Flvcr1aﬂ/ﬂ and Flvcr1aﬂ/ﬂ;alb-cre mice, untreate
cinylacetone (SA) (n ¼ 4). (F) qRT-PCR analysis of Ho-1, H-, and
Two-way analysis of variance with Bonferroni post-test analysisProtein Extraction and Western Blotting
Tissue and cell proteins were extracted as reported previ-
ously17 and concentration was determined using the Bio-Rad
protein assay system (Bio-Rad, Munich, Germany). Fifty mi-
crograms total protein extracts were separated on 8%12%
sodium dodecyl sulfate polyacrylamide gel electrophoresis and
analyzed by Western blotting using antibodies against HO-1
(Stressgen, Victoria, Canada), L- and H-ferritin (kindly pro-
vided by Sonia Levi), ferroportin (Fpn; Alpha Diagnostic Intl.
Inc, San Antonio, TX), CYP1A1, CYP3A, CYP2E1, and actin (Santa
Cruz Biotechnology, Inc., Dallas, TX).
Histology
Tissues were ﬁxed in 10% formalin overnight at room
temperature and embedded in parafﬁn. Microtome sections,
5-mm thick, were stained with Perl’s reaction followed
by methanol 3,3-diaminobenzidine (Boehringer Mannheim,
Germany) development.
ALAS Activity
ALAS activity was assayed by measuring ALA formation in
liver homogenates after glycine addition.
CYP Activity
CYP1A1 activity was assessed by measuring
ethoxyresoruﬁn-O-deethylase activity in liver microsomes
using 7-ethoxyresoruﬁn as a substrate. CYP3A activity was
assessed by measuring conversion of the substrate proluciferin-
PFBE to luciferin (V8901 P450-Glo CYP3A4 Assay; Promega,
Madison, WI). CYP2E1 activity was determined by assaying the
hydroxylation of p-nitrophenol to 4-nitrocatechol in the liver
microsomal fraction.
Statistical Analysis
Results were expressed as mean  SEM. Comparisons be-
tween 2 groups were performed with 2-sided Welch t tests and
among more than 2 groups with 1- or 2-way analysis of vari-
ance followed by Bonferroni post test. P values <.05 were
regarded as signiﬁcant (*P <. 05; **P < .01; ***P < .001;
****P < .0001).
See also Supplementary Material.Results
Generation of Liver-Speciﬁc Flvcr1a
Knockout Mice
To study the function of the heme exporter FLVCR1a in
the liver, we generated a liver-speciﬁc Flvcr1a knockout
mouse (Supplementary Figure 1A). Liver-speciﬁc Flvcr1aassociated with heme biosynthesis. Data on ALA-treated
malondialdehyde (MDA) (B) content in the liver (n ¼ 4). (C)
r1a, Ho-1, Fpn, Txnrd1, Sod1, Alas1, Flvcr1b, and TfR1mRNA
n species (ROS) production on primary hepatocytes isolated
d or treated with 5 mM ALA or 5mM ALA and 0.5 mM suc-
L-Ft mRNA level in ALA-treated primary hepatocytes (n ¼ 6).
was performed. *P < .05; **P < .01; ***P < .001; ****P < .0001.
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pected Mendelian ratio and were viable and fertile.
Flvcr1aﬂ/ﬂ;alb-cre mice showed the recombinant allele
only in the liver (Supplementary Figure 1B) and a strong
reduction of hepatic Flvcr1a expression (Supplementary
Figure 1C and D). As expected, Flvcr1a mRNA could not
be detected in primary hepatocytes isolated from
Flvcr1aﬂ/ﬂ;alb-cre mice (Supplementary Figure 1E), de-
monstrating that this mouse is a liver-speciﬁc knockout
model for Flvcr1a.
Flvcr1aﬂ/ﬂ;alb-cre mice showed no gross liver abnor-
malities (Supplementary Figure 1F). Blood analysis did not
reveal any difference between Flvcr1aﬂ/ﬂ;alb-cre and
Flvcr1aﬂ/ﬂ mice (Supplementary Table 1).Figure 4. Flvcr1a deﬁciency affects liver homeostasis after dexam
dexamethasone-treated Flvcr1aﬂ/ﬂ and Flvcr1aﬂ/ﬂ;alb-cre mice a
(A) n ¼ 5. (B) n ¼ 5. (C, E, F) Quantitative real-time polymerase
Flvcr1b, and TfR1 mRNA level (n ¼ 5). (D) Representative West
with Bonferroni post-test analysis was performed. *P < .05; **PFlvcr1a Deletion in the Liver Results in
Altered Hepatic Heme/Iron Homeostasis
To evaluate if the deletion of Flvcr1a alters hepatic heme
homeostasis, we analyzed the livers of 2- and 6-month-old
Flvcr1aﬂ/ﬂ;alb-cre compared with those of an Flvcr1aﬂ/ﬂ
counterpart. Hepatic heme and iron content were compa-
rable at 2 months of age, but were signiﬁcantly higher in
6-month-old Flvcr1aﬂ/ﬂ;alb-cre than in Flvcr1aﬂ/ﬂ mice
(Figure 1A and B). Iron accumulation in 6-month-old
Flvcr1aﬂ/ﬂ;alb-cre mice was further conﬁrmed by Perl’s
staining on liver sections (Figure 1B). Consistently,
Flvcr1aﬂ/ﬂ;alb-cre mice showed an enhanced HO activity
as well as an increased bilirubin excretion in the bileethasone-induced cytochrome synthesis. Data on the liver of
re shown. Heme (A) and malondialdehyde (MDA) (B) content.
chain reaction analysis of Flvcr1a and Ho-1, Txnrd1, Alas1,
ern blot of L-Ft protein (n ¼ 4). Two-way analysis of variance
< .01; ***P < .001.
May 2014 Role of Flvcr1a in Liver Function in Mice 1331compared with Flvcr1aﬂ/ﬂ mice (Figure 1C). In addition,
Flvcr1aﬂ/ﬂ;alb-cre mice showed increased lipid peroxidation
in the liver (Figure 1D). The analysis of hepatic gene
expression revealed that Flvcr1aﬂ/ﬂ;alb-cre mice up-
regulated genes that encode for proteins involved in heme
metabolism (Ho-1),18,19 iron export (Fpn)20,21 and storage
(H- and L-Ferritin),22 and antioxidant response (Txnrd1,
g-gcs, Sod1),23 compared with Flvcr1aﬂ/ﬂ mice (Figure 1E
and F; Supplementary Figure 2 for gene expression analysis
of 2-month-old mice). On the other hand, expression of the
other known heme exporter Abcg2 was not increased in the
liver of Flvcr1aﬂ/ﬂ;alb-cre mice (Supplementary Figure 3),
indicating that no other heme exporter was able to
compensate for the lack of Flvcr1a.FLVCR1a Is Required to Export Heme on
Heme Accumulation Inside Hepatocytes
The phenotype of liver-speciﬁc Flvcr1a knockout mice
suggests that FLVCR1a-mediated heme export prevents
hepatic heme accumulation. To further address this point,Figure 5. Flvcr1a deﬁ-
ciency affects liver homeo-
stasis after Be(a)P-induced
cytochrome synthesis.
Data on the liver of Be(a)P-
treated Flvcr1aﬂ/ﬂ and
Flvcr1aﬂ/ﬂ;alb-cre mice are
shown. Heme (A) and
malondialdehyde (MDA) (B)
content (n ¼ 6). (C, E)
Quantitative real-time poly-
merase chain reaction
analysis of Flvcr1a, Ho-1,
and Fpn and of Alas1 and
Flvcr1bmRNA level (n¼ 8).
(D) Representative Western
blot of L-Ft protein (n ¼ 4).
Two-way analysis of
variance with Bonferroni
post-test analysis was per-
formed. *P< .05; **P< .01;
***P < .001; ****P < .0001.mice were injected with hemin, the substrate of FLVCR1a.
One hour after heme injection, heme accumulated in the
liver of both Flvcr1aﬂ/ﬂ;alb-cre and Flvcr1aﬂ/ﬂ mice at the
same extent, but bilirubin production was signiﬁcantly
higher in Flvcr1aﬂ/ﬂ;alb-cre mice than in Flvcr1aﬂ/ﬂ mice,
likely because of the enhanced HO activity (Figure 2A and B).
Consistently, if animals were pretreated with the heme
analog Tin-Protoporphyrin IX that inhibits HO, before heme
injection, Flvcr1aﬂ/ﬂ;alb-cre mice showed a signiﬁcantly
higher hepatic heme content 1 hour after heme infusion
compared with control mice (Figure 2C). When we injected
mice with Tin-Protoporphyrin IX alone, we found it accu-
mulated more in the liver of Flvcr1aﬂ/ﬂ;alb-cre mice than in
that of Flvcr1aﬂ/ﬂ controls (Figure 2D), strengthening the
FLVCR1a export function. Measurement of heme content in
the bile at 1 hour after heme injection demonstrated that it
was excreted at the same extent in both Flvcr1aﬂ/ﬂ;alb-cre
and Flvcr1aﬂ/ﬂ mice (Supplementary Figure 4A), suggesting
that Flvcr1a did not export heme in the bile but likely vs the
bloodstream. Accordingly, the analysis of a human hep-
atocarcinoma cell line, HepG2, overexpressing Flvcr1a-myc,BA
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May 2014 Role of Flvcr1a in Liver Function in Mice 1333showed that FLVCR1a localized at the plasma cell mem-
brane, along the sinusoidal surface (Supplementary
Figure 4B).
Data shown in Figure 2C indicate that the enhanced HO
activity was able to compensate for the lack of FLVCR1a to
maintain heme content in the normal range on transient
heme accumulation. This was further demonstrated by the
analysis of gene expression. On heme treatment, Flvcr1aﬂ/ﬂ
mice showed a strong induction of Flvcr1a in the liver, as
well as an up-regulation of Ho-1, Fpn, H- and L-ferritin.
Flvcr1aﬂ/ﬂ;alb-cre mice that were unable to induce Flvcr1a,
showed a stronger induction of the heme degradation and
iron storage/export pathways, as an attempt to compensate
for the lack of heme export (Figure 2E and F). This was not
sufﬁcient to control oxidative stress, as demonstrated by the
signiﬁcantly higher induction of the antioxidant genes in the
liver of Flvcr1a-deleted mice after heme injection
(Figure 2E).
These data demonstrate that FLVCR1a is a heme
exporter in hepatocytes that works in close association with
the heme degradation pathway to maintain heme/iron
homeostasis.BA
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Strictly Associated With Heme Biosynthesis
The liver is, at the same time, one of the organs with the
highest rate of heme synthesis and the main body site
deputed to the detoxiﬁcation of heme coming from the
bloodstream. We asked in which of these processes is
FLVCR1a mainly involved. To address this point, we treated
mice with the heme precursor ALA or with the hemolytic
agent phenylhydrazine, to promote heme synthesis or heme
recovery from the bloodstream, respectively.
Although we did not observe any difference after phenyl-
hydrazine treatment (Supplementary Results, Supplementary
Figure 5), increased heme content was found in the liver of
Flvcr1aﬂ/ﬂ;alb-cre mice compared with Flvcr1aﬂ/ﬂ mice after
ALA treatment, suggesting that on de novo synthesis, heme
accumulated in the liver when FLVCR1a was absent
(Figure 3A). This resulted in a marked increase in the hepatic
lipid peroxidation index (Figure 3B). Interestingly, Flvcr1a
was strongly induced by ALA treatment in the liver of
Flvcr1aﬂ/ﬂ mice (Figure 3C). On the other hand, the genes
involved in heme and iron metabolism, such as Ho-1 and Fpn,
were up-regulated to an higher extent in the liver of
Flvcr1aﬂ/ﬂ;alb-cremice than in that ofFlvcr1aﬂ/ﬂmice, and this
was associated with a higher induction of the genes of the
antioxidant response (Figure 3C). Conversely, we observed a
reduced expression of Alas1, Flvcr1b, and Tfr1 in the liver of
Flvcr1aﬂ/ﬂ;alb-cre comparedwith Flvcr1aﬂ/ﬂmice (Figure 3C),=
Figure 6. The increase of cytosolic heme pool size due to Flvcr1
activity. Data on the liver of Flvcr1aﬂ/ﬂ and Flvcr1aﬂ/ﬂ;alb-cre mic
left and right, respectively. (A) ALAS1 expression and ALAS a
(C) Cytosolic and microsomal heme content (n ¼ 5). (D) Quantita
Cyp1a1 mRNA level and representative Western blot of CYP3A/C
way analysis of variance with Bonferroni post-test analysis wassuggesting an attenuation of the heme biosynthetic pathway
in these animals. These results were conﬁrmed in vitro on
primary hepatocytes treated with ALA (Figure 3DF;
Supplementary Material).
These data indicate that FLVCR1a-mediated heme export
function is strictly associated with heme synthesis.FLVCR1a-Mediated Heme Export Function Is
Associated With CYP Induction
In the liver, most of the newly synthesized heme is
committed to CYP synthesis. To test whether FLVCR1a
function is linked to heme synthesis stimulation on cyto-
chromes induction, we treated our mice with inducers of 3
distinct classes of CYPs.
Firstly, we injected mice with dexamethasone, an inducer
of CYP3A. Dexamethasone treatment caused an increase in
heme content in the liver of Flvcr1aﬂ/ﬂ;alb-cre mice, that was
almost negligible in Flvcr1aﬂ/ﬂ counterpart (Figure 4A). This
effect was abrogated by co-treatment with the inhibitor of
heme biosynthesis, succinylacetone (Figure 4A). As a conse-
quence of heme accumulation, a higher amount of lipid per-
oxides was generated on dexamethasone treatment in the
liver of Flvcr1aﬂ/ﬂ;alb-cre mice compared with Flvcr1aﬂ/ﬂ
mice (Figure 4B). The analysis of gene expression demon-
strated that Flvcr1a was induced in the liver of Flvcr1aﬂ/ﬂ
mice after dexamethasone treatment, as occurred on ALA
treatment (Figure 4C). On the other hand, the heme-, iron-,
and stress-related genes were induced to a higher extent in
the liver of dexamethasone-treated Flvcr1aﬂ/ﬂ;alb-cre mice
compared with the Flvcr1aﬂ/ﬂ counterpart (Figure 4C–E),
suggesting that the higher induction of these genes
compensated for the lack of Flvcr1a. In addition, genes
involved in heme biosynthesis, such as Alas-1, Flvcr1b, and
Tfr1, were found to be signiﬁcantly less expressed in
Flvcr1aﬂ/ﬂ;alb-cre mice compared with Flvcr1aﬂ/ﬂ mice after
dexamethasone treatment (Figure 4F).
Similar results were obtained when mice were treated
with benzo(a)pyrene (Be[a]P), an inducer of CYP1A1 and
CYP1A2 (Figure 5, Supplementary Figure 6), and imidazole,
an inducer of CYP2E1 (Supplementary Results;
Supplementary Figure 7). Because the induction of Alas1 8h
after Be(a)P injection was comparable in Flvcr1aﬂ/ﬂ;alb-cre
and Flvcr1aﬂ/ﬂ (Supplementary Figure 8), the difference
found at 16 hours post injection likely indicates that the
heme biosynthetic pathway was switched off earlier in
Flvcr1a-deleted mice than in its wild-type counterparts, as
an attempt to compensate for the excess of heme accumu-
lated in the liver.
Collectively, these data indicate that FLVCR1a-mediated
heme export is associated with CYP induction.a deﬁciency inhibits ALAS1 and induces HO-1, impairing CYP
e after dexamethasone or B(a)P treatment are shown on the
ctivity (n ¼ 8). (B) HO-1 expression and HO activity (n ¼ 8).
tive real-time polymerase chain reaction analysis of Cyp3a11/
YP1A1 protein. (E) CYP3A and CYP1A1 activity (n ¼ 7). Two-
performed. *P < .05; **P < .01; ***P < .001; ****P < .0001.
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Regulating Heme Synthesis and Degradation
In the previous section, we showed that Ho-1 and Alas1
mRNA levels were higher and lower, respectively, in the
liver of dexamethasone-, Be(a)P-, or imidazole- treated
Flvcr1aﬂ/ﬂ;alb-cre compared with Flvcr1aﬂ/ﬂ mice, suggest-
ing that heme degradation is increased and heme synthesis
is inhibited when FLVCR1a-mediated heme export is
blocked. Consistently, Ho-1 was found up-regulated and
Alas1, as well as Flvcr1b, down-regulated in the liver of
sickle cell anemia and b-thalassemia mice, in which Flvcr1a
levels were strongly decreased (Supplementary Figure 9).
This observation strengthens the idea that Flvcr1a deletion/
down-regulation leads to the coordinated induction of heme
degradation and down-regulation of the heme biosynthetic
pathway. To evaluate this point, we analyzed HO-1 as well
as ALAS1 protein and activity in the liver of Flvcr1aﬂ/ﬂ;alb-
cre and Flvcr1aﬂ/ﬂ mice, treated with dexamethasone or
Be(a)P. After the stimulation of CYP synthesis, HO-1 and
ALAS1 expression were induced in the liver of both
Flvcr1aﬂ/ﬂ;alb-cre and Flvcr1aﬂ/ﬂ mice (Figure 6A and B).
HO-1 induction was signiﬁcantly higher and ALAS1
expression was markedly reduced in the liver of Flvcr1aﬂ/ﬂ;
alb-cre mice compared with Flvcr1aﬂ/ﬂ counterparts. This
correlated with the enzymatic activities of HO-1 and ALAS1,
which were respectively higher and lower in the liver of
Flvcr1aﬂ/ﬂ;alb-cre mice than in that of Flvcr1aﬂ/ﬂ animals
(Figure 6A and B). HO-1 induction as well as ALAS1 inhi-
bition were likely mediated by heme overload occurring in
Flvcr1aﬂ/ﬂ;alb-cre mice. Consistently, after the stimulation of
CYP synthesis, heme accumulated to a higher extent in the
cytosolic fraction of Flvcr1aﬂ/ﬂ;alb-cre mice compared with
Flvcr1aﬂ/ﬂ controls. On the other hand, heme content
was signiﬁcantly lower in the microsomal fraction of
Flvcr1aﬂ/ﬂ;alb-cre mice than in that of Flvcr1aﬂ/ﬂ animals
(Figure 6C). As microsomal heme reﬂects the heme fraction
contained in CYPs, we measured mRNA and protein
expression and enzymatic activity of CYP3A and CYP1A1 in
the livers of our mice. In agreement with heme levels,
CYP3A and CYP1A1 mRNA, protein levels and activities
were signiﬁcantly lower in the livers of dexamethasone- and
Be(a)P-treated Flvcr1aﬂ/ﬂ;alb-cre mice than in those of
treated-Flvcr1aﬂ/ﬂ animals (Figure 6D and E). Similar results
were obtained when mice were treated with imidazole
(Supplementary Results; Supplementary Figure 10).
On the enhancement of heme demand, Flvcr1a deletion
resulted in an expansion of the cytosolic heme pool that
stimulates heme degradation and inhibits heme and CYP
synthesis.=
Figure 7. Heme overload as well as heme synthesis inhibition de
type mice after dexamethasone or B(a)P treatment are shown o
activity and HO activity (n ¼ 5). (B) Representative Western blo
activity (n ¼ 6). Data on the liver of 6-month-old Flvcr1aﬂ/ﬂ and
activity and HO activity (n ¼ 5). (D) Quantitative real-time polyme
and representative Western blot of CYP1A1/CYP3A protein (n ¼
of variance with Bonferroni post-test analysis and unpaired T te
the upper and bottom panel, respectively. (F) Illustration showing
Material). *P < .05; **P < .01; ***P < .001; ****P < .0001.To test whether the main determinant for CYP expres-
sion/function was the size of heme pool or the rate of heme
synthesis, both impaired in Flvcr1a-deleted liver, we treated
wild-type mice with dexamethasone or Be(a)P alone or
together with hemin, to mimic heme overload occurring in
Flvcr1aﬂ/ﬂ;alb-cre mice, or with succinylacetone or DL-
penicillamine, 2 inhibitors of heme biosynthesis. As ex-
pected, dexamethasone and Be(a)P treatment caused a
marked increase in ALAS1 activity as well as in CYP
expression/activity, and HO-1 expression/activity was only
slightly induced (Figure 7A and B). Hemin co-treatment
signiﬁcantly reduced hepatic ALAS1 activity, while
increasing HO-1 expression/activity, compared with mice
treated with dexamethasone or Be(a)P only (Figure 7A and B).
This correlated nicely with a reduced expression and
activity of CYPs (Figure 7B). Similarly, we observed that
co-treatment with Be(a)P and the ALAS-inhibitor DL-peni-
cillamine decreased ALAS activity as well as the expression
and activity of CYP1A1 (Figure 7A and B, right). Adminis-
tration of succinylacetone, a heme synthesis inhibitor acting
on 5-aminolevulinic acid dehydratase downstream of
ALAS1, caused a feedback up-regulation of ALAS1 activity,
as expected, but a decrease in CYP3A activity, as a conse-
quence of reduced heme availability (Figure 7A and B, left).
We can conclude that the effect of heme overload on cyto-
chrome function parallels that of heme synthesis inhibition,
fostering the concept that cytochrome function is strictly
associated to de novo heme production rather than to heme
pool size itself.
As further conﬁrmation, we observed that 6-month-old
Flvcr1aﬂ/ﬂ;alb-cre mice showed a reduction in ALAS1 ac-
tivity as well as an increase in HO activity (Figure 7C). This
misbalance in heme synthesis/degradation resulted in a
reduced CYP expression at both mRNA and protein level
(CYP1A1 and CYP3A, Figure 7D; CYP2E1, Supplementary
Figure 11) and reduced CYP activity (Figure 7E).
These data indicate that FLVCR1a-mediated heme export
in hepatocytes controls the expansion of the heme pool,
which in turns determines the balance between heme syn-
thesis and degradation and CYP activity.Discussion
Here we showed that FLVCR1a is essential for the main-
tenance of heme and iron homeostasis in the liver and that its
function is strictly associated with the heme biosynthetic
process that is crucial for the control of CYP activity.
Previous studies demonstrated that FLVCR1a exerts a
detoxifying function in macrophages and erythroid cells, bycrease CYP expression and activity. Data on the liver of wild-
n the upper left and upper right panels, respectively. (A) ALAS
ts of HO-1 and CYP3A/CYP1A protein, and CYP3A/CYP1A1
Flvcr1aﬂ/ﬂ;alb-cre mice are shown on bottom panel. (C) ALAS
rase chain reaction analysis of Cyp1a1/Cyp3a11 mRNA level
5). (E) CYP1A1 and CYP3A activity (n ¼ 5). One-way analysis
st analysis with Welch’s correction was performed on data in
FLVCR1a mood of action in the liver (see also Supplementary
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LIVERexporting heme excess.11,13,14 Our results indicate that
FLVCR1a is similarly important in the liver, as its deletion
leads to progressive heme and iron loading and to the
compensatory up-regulation of the genes responsible for
heme degradation and iron storage. Consistently with our
ﬁnding in mice, Flvcr1 was found mutated in human sub-
jects with mild hepatic iron overload.24
Our data show that FLVCR1a export function is associ-
ated with heme biosynthesis in agreement with data
showing that ALA treatment causes heme accumulation in
Flvcr1a-silenced HeLa cells.13 In addition, we observed a
concerted up-regulation of Flvcr1a and Flvcr1b, Alas1, and
TfR1 in the liver of ALA-treated wild-type mice that
strengthens the link between FLVCR1a function and heme
biosynthesis.
More than half of the hepatic production of heme is used
for the formation of CYPs,25,26 which are engaged in steroid
metabolism and in the oxidative metabolism of foreign
compounds, including pharmaceutical drugs.10,15,27 Our
data showed that Flvcr1a is up-regulated after CYP induc-
tion, suggesting that its function is strictly associated with
enhanced heme demand to support cytochrome induction.
Similarly, Alas1 as well as Flvcr1b and TfR1 are up-regulated
to sustain newly heme synthesis in such condition.
Because either a deﬁciency or an excess of heme is toxic
to the cell, hepatic heme production has to be tightly
controlled. Previous works showed that in primary cultures
of adult rat hepatocytes, 20% of newly formed heme is
converted to bile pigments, and 80% is used for the for-
mation of hemoproteins, mainly CYPs.28 Our data indicate
that not only heme degradation, but also FLVCR1a-mediated
heme export, is critical to ensure that the amount of avail-
able heme matches cell requirements. The alteration of one
of these pathways, heme synthesis, degradation or export, in
hepatocytes leads to an imbalance in heme homeostasis. In
particular, FLVCR1a deletion causes an increase in the
cytosolic heme fraction, when heme demand is increased to
support CYP induction.
The cytosolic heme fraction contains a pool of newly
synthesized heme that serves both precursor and regulatory
functions.10 The free heme pool controls heme biosynthesis,
through the regulation of ALAS1. If increased, the regulatory
heme pool may repress ALAS1,7 and its depletion causes
ALAS1 induction.10 Our results indicate that ALAS1 induc-
tion occurs in wild-type as well as in Flvcr1a-null mice
shortly after cytochrome stimulation, to sustain heme
synthesis for cytochrome formation. Then, Alas1 down-
regulation occurs earlier in Flvcr1a-null mice than in wild-
type animals because of the negative feedback exerted by
the expanded cytosolic free heme pool. This is in agreement
with many observations, according to which the addition of
heme in hepatocyte cultures inhibits the drug-induced
synthesis of ALAS.29–33 Although xenobiotics might have
some primary inducing effect on hepatic ALAS1,34,35 many
chemical inducers are believed to increase ALAS1 by
depleting the free heme pool in hepatocytes.10 This is in
agreement with our observation in wild-type mice in which
ALAS1 expression, CYP activity, and microsomal heme are
increased, and cytosolic heme levels are reduced after drugtreatment. Conversely, liver-speciﬁc Flvcr1a-null mice
showed an expansion of the cytosolic heme pool, suggesting
that Flvcr1a deletion promotes intracellular heme accumu-
lation, preventing the depletion of the free heme pool as a
stimulus for ALAS1 induction and on the contrary, pro-
moting its inhibition.
In liver-speciﬁc Flvcr1a -null mice, the decreased heme
synthesis well correlates with a reduction of CYP expression
and activity, in line with the previous observation that the
enhancement in heme synthesis is required to sustain the
induction/activity of CYPs.26,36–38 Conversely, when a bolus
of hemin is administered to experimental animals, the
induction/activity of CYPs is greatly suppressed and this
effect is considered to be the result of inhibition of heme
biosynthesis by ALAS1.39,40 Short-term hemin administra-
tion is known to both increase HO1 expression41 and
interfere with the formation of CYP.40 Consistently, drug-
treated Flvcr1a-null mice showed a signiﬁcantly higher in-
duction of HO1 and reduction in the expression and activity
of ALAS1 and CYPs compared with wild-type animals,
indicating that heme accumulation resulting from Flvcr1a
deletion resembles what occurs after hemin administration.
In conclusion, the block of heme export due to Flvcr1a
deletion promotes the expansion of the cytosolic heme pool,
thus leading to ALAS inhibition and HO induction. We pro-
pose that the lack of FLVCR1a causes a reduction in the
newly synthesized heme, impairing both CYP expression
and activity (Figure 7F). It appears that in the hepatocytes,
heme is formed in slight excess over its metabolic needs28
and its levels are maintained adequate by a combination
of synthetic, degradative, and export mechanisms, suggest-
ing that they are equipped with a “sensing” system to
monitor changes in the size of “uncommitted” heme pool.
We can speculate that FLVCR1a is part of this sensing
system and that, by sensing heme levels and exporting heme
excess out of the cell, it controls the size of the cytosolic
heme pool, playing a crucial regulatory role in cell meta-
bolism and in the maintenance of a proper oxidative status.
We expect that mutations in Flvcr1a and/or pathologic sit-
uations that affect its expression can result in a reduced CYP
activity, altering drug metabolism, in particular in in-
dividuals that routinely assume drugs for therapeutic
purposes.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://dx.doi.org/10.1053/
j.gastro.2014.01.053.References
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